Cerebrospinal fluid from L-dopa-treated Parkinson's disease patients is dystrophic for various neural cell types ex vivo: Effects of astroglia

Experimental Neurology

Volumn 154, Issue 2, 1998, Pages 452-463

  Colombo, J A ^a   Napp, M I ^a  

^a CEMIC   (Argentina)

Author keywords

Astroglia; Cerebrospinal fluid; Chromaffin cells; Parkinson's disease; Striatum; Ventral mesencephalon

Indexed keywords

LEVODOPA;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CEBIDAE; CELL SURVIVAL; CELL TRANSPLANTATION; CEREBROSPINAL FLUID; CHROMAFFIN CELL; CONTROLLED STUDY; CORPUS STRIATUM; FETUS; HUMAN; MACROGLIA; NEUROTROPISM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0032424321     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6910     Document Type: Article

References (40)

1. Amano S., Ohashi M., Ishiko T., Hazama F. Humoral factors derived from glial cells protect cultured neuroblastoma cells against glutamate toxicity. Brain Res. 645:1994;347-350.
2. Blin J., Bonnet A-M., Agid Y. Does levodopa aggravate Parkinson's Disease. Neurol. 38:1988;1410-1416.
3. Blunt S. B., Jenner P., Marsden C. D. Suppressive effect of L-Dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov. Dis. 8:1993;129-133.
4. Brewer G. J., Torricelli J. R., Evege E. K., Price P. J. Optimized survival of hippocampal neurons in B-27-supplemented Neurobasal, a new serum free medium combination. J. Neurosci. Res. 35:1993;567-576.
5. Bronstein D. M., Perez-Otano I., Sun V., Mullis Sawin S. B., Chan J., Wu G. C., Hudson P. M., Kong L-Y., Hong J-S., McMillian M. K. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res. 704:1995;112-116.
6. Carvey P. M., Ptak L. R., Lo E. S., Lin D., Buhrfiend C. M., Goetz C. G., Klawans H. L. Levodopa reduces the growth promoting effect of striatal extracts on rostral mesencephalic tegmentum cultures. Exp. Neurol. 114:1991;28-34.
7. Carvey P. M., Ptak L. R., Nath S. T., Sierens D. K., Mufson E. J., Goetz C. G., Klawans H. L. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp. Neurol. 120:1993;149-152.
8. Colombo J. A., Micheli F., Napp M., Medana A., Depaoli J. Parkinson's disease CSF fromLin vitro. 1995;Fourth IBRO World Congress, Kyoto.
9. Colombo J. A., Napp M., Medana A. Regional differences in in vitro growth of neural cell processes during development. Int. J. Devl. Neurosci. 14:1996;497-505.
10. Delfino M., Napp M., Colombo J. A. Developmental differences in cell growth among brain regionsin vitro: 1995;Fourth IBRO Congress, Kyoto.
11. Engele J., Schubert D., Bohn M. C. Conditioned media derived from glial cell lines promote survival and differentiation of dopaminergic neuronsin vitro: J. Neurosci. Res. 30:1991;359-371.
12. Hao R., Norgren R. B., Lau Y-S., Pfeiffer R. F. Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture. Neurology. 45:1995;138-142.
13. Hastings T. S., Zigmond M. J. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J. Neural Transm. 49:1997;103-110.
14. Herman J-P., Abrous N. D. Dopaminergic neural grafts after fifteen years: results and perspectives. Progr. Neurobiol. 44:1994;1-35.
15. Hoffer B. J., Hoffman A., Bowenkamp K. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neuronsin vivo. Neurosci. Lett. 182:1994;107-111.
16. Hornykiewicz O., Pifl C., Kish S. J., Shannak K., Schingnitz G. Biochemical changes in idiopatic Parkinson's disease, aging and MPTP Parkinsonism: Similarities and differences. Parkinsonism and Aging. 1989;Raven Press, New York. p. 57-67.
17. Hornykiewicz O. Ageing and neurotoxins as causative factors in idiopathic Parkinson's Disease-A critical analysis of the neurochemical evidence. Prog. Neuropsychopharm. Biol. Psychol. 13:1989;19-328.
18. Hornykiewicz O. The primary site of dopamine neuron damage in Parkinson's disease: Substantia nigra or striatum. Mov. Disorders. 7:1992;288.
19. Hudson J., Granholm A-C., Gerhardt G. A. Glial cell line-derived nerotrophic factor augments midbrain dopaminergic circuitsin vivo. Brain Res. Bull. 36:1995;425-432.
20. Jones D. Use, misuse and role of multiple-comparison procedures in ecological and agricultural entomology. Environm. Entomol. 13:1984;635-649.
21. Krobert K., Lopezcolberg I., Cunningham L. A. Astrocytes promote or impair the survival and function of embryonic ventral mesencephalon co-grafts: Effects of astrocyte age and expression of recombinant brain derived neurotrophic factor. Exp. Neurol. 145:1997;511-523.
22. Langeveld C. H., Jongenelen C. A. M., Schepens E., Stoof J. C., Bast A., Drukarch B. Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development. Neurosci. Lett. 192:1995;13-16.
23. Lopez Lozano J., Brera B. CPH Neural Transplantation Group. Neural transplants in Parkinson's Disease. Transplant Proc. 25:1993;1005-1011.
24. Manthorpe M., Rudge J. S., Varon S. Astroglial cell contributions to neuronal survival and neuritic growth. Fedoroff S., Vemadakis A. Astrocytes. 1986;315-376 Academic Press.
25. Maren T. H. The cerebrospinal fluid. Mountcastle V. Medical Physiology. 1974;1116-1141 Mosby, St. Louis.
26. Martin W. R. W., Palmer M. R., Patlak C. S., Calne D. B. Nigrostriatal function in humans studied with positron emission tomography. Ann. Neurol. 26:1989;535-542.
27. Mattammal M. B., Chung H. D., Strong R. Confirmation of a dopamine metabolite in parkinsonian brain tissue by gas chromatography-mass spectrometry. J. Chromatogr. 614:1993;205-212.
28. Medana, A. M. Napp, V. Puissant, J. A. Colombo, 1994, Efecto de fluidos fisiológicos sobre cultivos primarios de estructuras prosencefálicas de rata fetal, XVIII Congreso Latinoamericano de Ciencias Fisiológicas, Montevideo, Uruguay.
29. Mena M. A., Casarejos M. J., Carazo A., Paino C. L., Garcia de Yebenes J. Glial conditioned medium protects fetal rat midbrain neurones in culture fromL. NeuroReport. 7:1996;441-445.
30. Murata M., Kanazawa I. Repeated L-Dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat. Neurosci. Res. 16:1993;15-23.
31. Mytilineou C., Han S-K., Cohen G. Toxic and protective effects ofL. J. Neurochem. 61:1993;1470-1478.
32. O'Malley E. K., Sieber B-A., Morrison R. S., Black I. B., Dreyfus C. F. Nigral type I astrocytes release a soluble factor that increases dopaminergic neuron survival through mecanisms distinct from basic fibroblast growth factor. Brain Res. 647:1994;83-90.
33. Olanow C. W., Kordower J. H., Freeman T. B. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurol. Sci. 19:1996;102-109.
34. Pardo B., Mena M. A., Casarejos M. J., Paino C. L., De Yerbenes J. G. Toxic effect of L-Dopa on mesencephalic cultures: protection with antioxidants. Brain Res. 682:1996;133-143.
35. Przedborski S., Jackson-Lewis V., Muthane U., Jiang H., Ferreyra M., Naini A. B., Fahn S. Chronic levodopa administration alters mitochondrial respiratory chain activity. Ann. Neurol. 34:1993;715-723.
36. Rajput A. H., Fenton M. E., Birdi S., Macaulay R. Is levodopa toxic to human substantia nigra. Mov. Dis. 12:1997;634-638.
37. Tanaka M., Sotomatsu A., Kanai H., Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J. Neurol. Sci. 101:1991;198-203.
38. Tomac A., Lindqvist L., Lin L-F. H., Ogren S. O., Young D., Hoffer B. J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNFin vivo. Nature. 373:1995;335-339.
39. Wüllner U., Löschmann P-A., Schulz J. B., Schmid A., Dringen R., Eblen F., Turski L., Klockgether T. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopamine neurones. NeuroReport. 7:1996;921-923.
40. Yu S. J., Lo E. S., Cochran E. J., Lin D. H., Faselis C. J., Klawans H. L., Carvey P. M. Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephalic culture. Exp. Neurol. 125:1994;15-24.